# Extracellular Vesicle Core

> **NIH NIH P30** · RHODE ISLAND HOSPITAL · 2024 · $208,547

## Abstract

Project Summary/Abstract
The COBRE Center for Stem Cells and Aging at Rhode Island Hospital established the unique Extracellular
Vesicle Core in July 2019. The aims of the Extracellular Vesicle Core are: 1) To provide the research community
at Rhode Island Hospital and outside of Rhode Island Hospital with expertise to support research in the field of
Extracellular Vesicle (EV). 2) To assist with EV experimental design, data collection, analysis, and storage, as
well as preparation for NIH, industry, or foundation grant submissions. 3) To enhance the collaboration and
translational research environment in the Rhode Island research community. 4) To become a financially
independent Core facility after Phase 3 of the COBRE. The Extracellular Vesicle Core instrumentation mainly
consists of two Thermo WX-40 ultracentrifuges, a Tangenx LHV tangential flow system, Applied Biosystems
ViiA™ 7 Real-Time PCR System with Twister robot, a Malvern NanoSight NS 500 with two lasers (405nm and
488nm), and a Fiber Cell Systems duet bioreactor. The Extracellular Vesicle Core is a state-of-the-art facility that
will continue to enhance collaboration and translational research in the hospital and university communities. In
collaboration with clinical doctors from Rhode Island Hospital, our Core has made significant contributions to
investigating the clinical significance of EVs as non-invasive “liquid biopsy” biomarkers for tracking the
effectiveness of disease therapy. This resulted in a $1.4 million grant in 2020 from Bristol Myers Squibb, where
approximately $350,000 was awarded to Dr. Quesenberry’s lab specifically for the Extracellular Vesicle Core.
Dr. John Reagan obtained $860,000 from Pfizer for his study of Acute Myeloid Leukemia, where EV-related
research was executed through the Extracellular Vesicle Core. Dr. Jill Kreiling got her NIH R01 in 2022, for the
study of the feasibility of using extracellular vesicles in saliva as biomarkers for Alzheimer’s disease where
$60,000 per year was committed to the Extracellular Vesicle Core in the next five years. In the last three years,
the Extracellular Vesicle Core has serviced 18 projects for 22 investigators from 15 different academic
departments at five Institutions (Brown University, Rhode Island Hospital, Women and Infants Hospital, the
University of Rhode Island, and Providence VA Medical Center). These projects demonstrate that the
Extracellular Vesicle Core will continue to play a crucial role in supporting regional projects and facilitating the
basic research and the translation of novel therapeutic approaches to the treatment and prevention of disease.

## Key facts

- **NIH application ID:** 10874437
- **Project number:** 5P30GM145500-02
- **Recipient organization:** RHODE ISLAND HOSPITAL
- **Principal Investigator:** Sicheng Wen
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $208,547
- **Award type:** 5
- **Project period:** 2023-07-01 → 2028-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10874437

## Citation

> US National Institutes of Health, RePORTER application 10874437, Extracellular Vesicle Core (5P30GM145500-02). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10874437. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*